◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 1877

Shanghai Junshi Biosciences Co., Ltd. (1877) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-11

Shanghai Junshi Biosciences Co., Ltd. (1877) operates in the Biotechnology industry and is headquartered in Shanghai, China with about 2,903 employees. Its market capitalization is roughly CNY 20 billion. In the fiscal year ended 2025-12-31, 1877 reported CNY 2.5B in revenue and (CNY 841M) in net income.

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China.

Interactive charts & full statements →

1877 Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total RevenueCNY 2.5BCNY 1.9BCNY 1.5BCNY 1.5B
Gross ProfitCNY 2.0BCNY 1.4BCNY 835MCNY 927M
Operating Income (EBIT)(CNY 925M)(CNY 1.3B)(CNY 2.5B)(CNY 2.7B)
Net Income(CNY 841M)(CNY 1.3B)(CNY 2.3B)(CNY 2.4B)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

1877 Free Cash Flow History

1877 Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total AssetsCNY 12.4BCNY 10.8BCNY 11.4BCNY 12.6B
Total LiabilitiesCNY 6.3BCNY 4.8BCNY 4.0BCNY 2.8B

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 1877 viewer.

Other Companies in Biotechnology

← 1876All “0-9” companies1878 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.